These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23565885)

  • 21. [Targeted nanomedicine in diagnostics and therapy of neurological diseases].
    Bertalan F; László B; Attila V
    Ideggyogy Sz; 2013 May; 66(5-6):155-63. PubMed ID: 23909015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early environmental regulation of forebrain glucocorticoid receptor gene expression: implications for adrenocortical responses to stress.
    Meaney MJ; Diorio J; Francis D; Widdowson J; LaPlante P; Caldji C; Sharma S; Seckl JR; Plotsky PM
    Dev Neurosci; 1996; 18(1-2):49-72. PubMed ID: 8840086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ontologies of drug discovery and design for neurology, cardiology and oncology.
    Vázquez-Naya JM; Martínez-Romero M; Porto-Pazos AB; Novoa F; Valladares-Ayerbes M; Pereira J; Munteanu CR; Dorado J
    Curr Pharm Des; 2010; 16(24):2724-36. PubMed ID: 20642429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inclusion of the glucocorticoid receptor in a hypothalamic pituitary adrenal axis model reveals bistability.
    Gupta S; Aslakson E; Gurbaxani BM; Vernon SD
    Theor Biol Med Model; 2007 Feb; 4():8. PubMed ID: 17300722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymer-based drug delivery devices for neurological disorders.
    Halliday AJ; Cook MJ
    CNS Neurol Disord Drug Targets; 2009 Jun; 8(3):205-21. PubMed ID: 19601818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intrathecal magnetic drug targeting for localized delivery of therapeutics in the CNS.
    Venugopal I; Habib N; Linninger A
    Nanomedicine (Lond); 2017 Apr; 12(8):865-877. PubMed ID: 28339319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucocorticoid receptor variants: clinical implications.
    DeRijk RH; Schaaf M; de Kloet ER
    J Steroid Biochem Mol Biol; 2002 Jun; 81(2):103-22. PubMed ID: 12137800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The stress system in the human brain in depression and neurodegeneration.
    Swaab DF; Bao AM; Lucassen PJ
    Ageing Res Rev; 2005 May; 4(2):141-94. PubMed ID: 15996533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kynurenines and the nervous system: therapeutic perspectives.
    Vécsei L
    J Neural Transm (Vienna); 2012 Feb; 119(2):107. PubMed ID: 22160490
    [No Abstract]   [Full Text] [Related]  

  • 30. An implication for post-transcriptional control: reciprocal changes of melanocortin receptor type 2 mRNA and protein expression in alopecia areata.
    Guo HW; Deng J; Yang XC; Yang SY; Liu BH; Hao F
    Med Hypotheses; 2011 Jan; 76(1):122-4. PubMed ID: 20884125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preface.
    Donev R
    Adv Protein Chem Struct Biol; 2016; 104():xiii-xv. PubMed ID: 27038380
    [No Abstract]   [Full Text] [Related]  

  • 32. Neurological drug development: a guide for a start-up biotech.
    Blackburn TP; Bezard E
    Neurobiol Dis; 2014 Jan; 61():1-5. PubMed ID: 23954447
    [No Abstract]   [Full Text] [Related]  

  • 33. [Multi-target therapeutics and new drug discovery].
    Xu Y; Li XJ
    Yao Xue Xue Bao; 2009 Mar; 44(3):226-30. PubMed ID: 19449518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What regulatory science can bring for CNS drug development.
    Gispen-de Wied C; Stoyanova-Beninska V
    Eur Neuropsychopharmacol; 2015 Jul; 25(7):967-8. PubMed ID: 26024929
    [No Abstract]   [Full Text] [Related]  

  • 35. Chemical & biological therapeutic approaches to neurological disorders.
    François I
    Drug News Perspect; 2010 Oct; 23(8):524-31. PubMed ID: 21031169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of glucocorticoid receptor gene expression by antidepressant drugs.
    Barden N
    Pharmacopsychiatry; 1996 Jan; 29(1):12-22. PubMed ID: 8852529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Development by researchers in academia of disease modifying drugs for neurological disorders].
    Ikeda S; Iwata A
    Rinsho Shinkeigaku; 2010 Nov; 50(11):837. PubMed ID: 21921463
    [No Abstract]   [Full Text] [Related]  

  • 38. Neuroregulation of the hypothalamus-pituitary-adrenal (HPA) axis in humans: effects of GABA-, mineralocorticoid-, and GH-Secretagogue-receptor modulation.
    Giordano R; Pellegrino M; Picu A; Bonelli L; Balbo M; Berardelli R; Lanfranco F; Ghigo E; Arvat E
    ScientificWorldJournal; 2006 Jan; 6():1-11. PubMed ID: 16432622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanomedicine: the future for advancing medicine and neuroscience.
    Tosi G; Ruozi B; Belletti D
    Nanomedicine (Lond); 2012 Aug; 7(8):1113-6. PubMed ID: 22931443
    [No Abstract]   [Full Text] [Related]  

  • 40. HPA axis dysregulation, NR3C1 polymorphisms and glucocorticoid receptor isoforms imbalance in metabolic syndrome.
    Martins CS; Elias D; Colli LM; Couri CE; Souza MC; Moreira AC; Foss MC; Elias LL; de Castro M
    Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27507764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.